Q4-FY26 · Q3 FY26
Revenue growth of 15% for FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
CORONAREMEDIES / Q4-FY26 / promises
Measure what management said.
Corona Remedies · A quarter-by-quarter view of forward statements and whether delivery is visible yet.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Management delivery ledger
Promises over time.
Q4-FY26 · Q3 FY26
PAT growth of 20% for FY26
The current-quarter record did not contain enough evidence of delivery; the item remains delayed for follow-up.
delayed
heuristic_v1
Q4-FY26 · Q3 FY26
Launch of GLP-1 injectable in March 2026
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1